Zacks Research Analysts Lower Earnings Estimates for SRPT

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Equities researchers at Zacks Research decreased their Q1 2027 EPS estimates for Sarepta Therapeutics in a research report issued to clients and investors on Tuesday, April 8th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $2.90 per share for the quarter, down from their previous estimate of $2.95. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.67 per share.

SRPT has been the topic of several other research reports. Royal Bank of Canada lowered Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their target price for the stock from $161.00 to $87.00 in a report on Monday, March 31st. HC Wainwright upgraded shares of Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 price target for the company in a research note on Wednesday, April 2nd. Cantor Fitzgerald restated an "overweight" rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Needham & Company LLC cut their target price on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a research note on Thursday, April 3rd. Finally, Morgan Stanley lowered their price target on Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating on the stock in a research report on Friday. Six analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $161.83.

Remove Ads

Sarepta Therapeutics Stock Up 1.8 %

Shares of Sarepta Therapeutics stock traded up $0.93 during trading hours on Wednesday, reaching $51.96. 635,259 shares of the company's stock were exchanged, compared to its average volume of 1,385,976. The stock has a market cap of $5.04 billion, a P/E ratio of 41.57 and a beta of 0.93. The company has a 50 day moving average of $88.11 and a two-hundred day moving average of $110.10. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a fifty-two week low of $48.01 and a fifty-two week high of $173.25.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. Captrust Financial Advisors grew its holdings in shares of Sarepta Therapeutics by 15.2% during the third quarter. Captrust Financial Advisors now owns 3,871 shares of the biotechnology company's stock worth $483,000 after purchasing an additional 511 shares during the last quarter. Stifel Financial Corp grew its holdings in Sarepta Therapeutics by 99.3% during the 3rd quarter. Stifel Financial Corp now owns 37,207 shares of the biotechnology company's stock worth $4,647,000 after acquiring an additional 18,537 shares during the last quarter. Kovitz Investment Group Partners LLC increased its position in Sarepta Therapeutics by 36.7% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 2,814 shares of the biotechnology company's stock valued at $322,000 after acquiring an additional 755 shares during the period. M&T Bank Corp raised its stake in shares of Sarepta Therapeutics by 8.5% during the third quarter. M&T Bank Corp now owns 4,462 shares of the biotechnology company's stock valued at $558,000 after acquiring an additional 349 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after purchasing an additional 44,306 shares during the period. Institutional investors own 86.68% of the company's stock.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.70% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.